MASLD Research Center
@MASLDResearch
Followers
222
Following
152
Media
45
Statuses
248
Honored to be supported by @AmCollegeGastro for our important work towards #HealthEquity for the #Hispanic #Latino community with chronic #liver disease @MASLDResearch @DrLoomba @UCSDHealth
#HispanicHeritageMonth Spotlight: Monica A. Tincopa, MD Dr. Tincopa is recognized for her professional achievements and unwavering dedication to diversity, culturally informed care, and health equity in gastroenterology and hepatology. ➡️ https://t.co/r5mdv9xwQe
#DiversityinGI
1
3
19
Looking forward to new collaborations @APASLnews - across the spectrum of SLD @shivsarin @l_suthat @japantimes @MASLDResearch @DrHuangDQ
2
3
40
International collaborative review on Clinical trial design, biomarkers & endpoints in MetALD https://t.co/rhdbR06YmJ
@AASLDtweets @EASLnews @MASLDResearch @AmCollegeGastro @INASL_Liver @APASLnews
1
15
47
Using NIT to assess semaglutide response using Phase 2b data- check it out!
Read open access via https://t.co/J37ZBiPwWt "Exploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients With MASH" #livertwitter #MASH #semaglutide #NITs
1
7
17
#Throwback COMMENT | C Hsu & @DrLoomba From NAFLD to MASLD: implications of the new nomenclature for preclinical and clinical research https://t.co/ofcR1MXM60
nature.com
Nature Metabolism - Non-alcoholic liver disease (NAFLD) is now metabolic dysfunction-associated steatotic liver disease (MASLD), emphasizing the key metabolic factors of obesity, insulin...
0
4
8
Join us as we celebrate #HispanicHeritageMonth highlighting important issues in #GI and #liver health for the #Latino community. @MASLDResearch @UCSDHealth @AASLDtweets
🌟Celebrate Hispanic Heritage Month with our new member network La LiGaH! Join @MonicaTincopa, @SandraQuezadaMD, Dr. Hugo Vargas & Dr. Silvio de Melo to explore health disparities & health equity concerns in GI and hepatology for the Latino community. 🔗 https://t.co/QzzLCmRYzZ
0
3
11
Learn from the experts at the Second Annual Thursday Liver Symposium! Cutting-edge updates, practical strategies, and leading voices in liver care—all in one event. Register now: https://t.co/g8ORkSWwLP
0
11
19
Such a great pleasure to have @SeragHashem at @UCSD_GI for our flagship Isenberg Lectureship! Learned a lot about HCC biomarkers and learning health system! An amazing treat for our faculty and trainees - true joys of academic medicine! @AmerGastroAssn
1
6
46
#Hispanic populations continue to ⬆️ in the US. Data from our study evaluating #LiverTransplant and waitlist outcomes is out https://t.co/BbUF8YmyEo Hispanic individuals had significantly ⬆️ time from last drink to listing raising c/f #ReferralBias
1
1
13
Phosphatidylethanol (PEth) testing could redefine how we classify SLD subtypes by uncovering under‑reported alcohol use and guiding treatment, trials & prognosis. Led by @DrLoomba @MASLDResearch @UCSD_GI 🔗 https://t.co/EX45IC8mVx
#LiverTwitter @AASLDtweets @EASLedu
2
33
65
Delighted to report our new paper on DGAT-2 silencing in MASH- Antisense oligonucleotide DGAT-2 inhibitor, ION224, for MASH (ION224-CS2): results of a RCT, phase 2b trial - The Lancet https://t.co/fN3CDePkLl
@AlkhouriNaim @MASLDResearch @CALonghurst
5
21
73
What to use Peth to differentiate SLD sub-type- here's how to do it based upon latest evidence- our collaborative piece with Hannes and Luis @MASLDResearch @UCSD_GI Emerging Role of Phosphatidylethanol Testing in Clinical Practice for ... https://t.co/mjxEhGrJ8v
@ebtapper
1
13
28
Welcoming @UCSD_GI fellowship class of 2025- so proud of our brilliant trainees @UCSDHealth - incredibly excited about their future and supporting their journey to become future leaders in GI @AmerGastroAssn @AASLDtweets @AmCollegeGastro
1
1
47
Drs. @Phil_Newsome7 and Rohit Loomba (@DrLoomba) review the pharmacological treatments in advanced development for metabolic dysfunction–associated #steatohepatitis. 📑 @JClinicalInvest: https://t.co/2SmqyhaeJZ
0
7
19
Original Article Disparities in screening and risk stratification for Hispanic adults with metabolic dysfunction–associated steatotic liver disease Tincopa et al. #LiverX
https://t.co/HOXV5bjrY3
0
5
22
🥇🔬UC San Diego is ranked #1 among the best universities for Gastroenterology and Hepatology Research by U.S. News & World Report! Proud of the Division of Gastroenterology and Hepatology for outstanding innovation and impact. @UCSD_GI @MASLDResearch #ResearchExcellence
0
1
16
Thanks @BritSocGastro for a very special session with @WenhaoLi29 Amy Johnson who talked about their experience @MASLDResearch @UCSDalumni as BSG Liver Fellow! Thanks @QAnstee @CoralHollywood for an amazing Liver faculty dinner
0
5
30
At #EASL2025, AASLD President Dr. Grace Su chaired 2 sessions, EASL/AASLD Endpoints Conference on #MetALD & ALD, and General Session I, underscoring our commitment to #liverdisease. Thanks to all who grabbed the #TLM25 Preliminary Guide at the Hub—see you in D.C. in November!
0
6
36
Can FIB-4 then VCTE detect sig. fibrosis in MetALD? = Yes read @LuisAntonioDiaz paper @MASLDResearch Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver diseas… https://t.co/51qstBC0kz
@AASLDtweets @ebtapper
pubmed.ncbi.nlm.nih.gov
A clinical care algorithm utilizing a stepwise approach with fibrosis-4 and VCTE shows adequate performance in detecting significant fibrosis in individuals with suspected MetALD.
0
15
43